Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multiple-dose RZ358 study in congenital hyperinsulinism
MOH_2020-06-07_008678Phase 2Completed
- Sponsor
- Rezolute, Inc.
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ersodetug in congenital hyperinsulinism (HI), sponsored by Rezolute, Inc. Primary endpoint: Not reported. Started May 2020; status: completed.
02
Drugs
ersodetug
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on MOH_2020-06-07_008678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-07_008678.